SecBot SecBot
Insider Cluster (3 insiders) ·Filed Mar 23, 2026

IMNM

Immunome Inc.
MIXED
Impact 5/10
Horizondays Processed7mo ago
Insider cluster: 2 insiders, $1.1M total
Actionable Insight ◆ Mixed

The CEO's open-market purchase is a positive signal, but it's offset by a director selling a slightly larger dollar amount. The overall activity is modest and not materially dilutive or accretive. Traders should monitor for follow-up transactions, especially additional buying from the CEO.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$20.75
T+0 close · Mar 22, 2026 · via day close
Latest settled
−10.70%
T+60 · $18.53
Vs SPY
−23.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 23 $20.75entry
  2. T+1 · 8mo ago −2.60%α −2.25% · $20.21
  3. T+5 · 8mo ago −6.99%α −3.42% · $19.30
  4. T+20 · 7mo ago +14.94%α +7.52% · $23.85
  5. T+60 · 5mo ago −10.70%α −23.76% · $18.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immunome Inc. saw mixed insider activity with CEO Clay Siegall purchasing $501K of stock while Director Philip Wagenheim sold $582K. The trades are modest in size relative to the company's $2.5B market cap, with the CEO's buying signaling confidence despite a director's exit.

Key Financial Metrics

Direction
mixed
Total Value
$1.1M
Insiders
3

Key Facts

  • CEO Clay Siegall purchased 25,450 shares in the open market for $500,601.50 at $19.67 per share on March 27, 2026.
  • Director Philip Wagenheim sold 28,200 shares for $582,330 at $20.65 per share on March 23, 2026.
  • CSO Jack Higgins gifted 6,291 shares (non-cash transaction) on March 30, 2026.
  • Total cluster value: $1.08M, representing 0.04% of the company's $2.5B market cap.

Financial Impact

$1.08M in net insider transactions over 7 days, with $501K in buying and $582K in selling. Non-cash gift of 6,291 shares adds no economic value.

insider sentimentshare ownership

Risk Factors

  • Director selling could indicate lack of confidence or portfolio rebalancing.
  • Low volume of insider trades limits the strength of the signal.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-IMNM-1775079580899

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026